anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Human Experience

In premarketing experience with oral risperidone, there were eight reports of acute risperidone overdosage with estimated doses ranging from 20 to 300 mg and no fatalities. In general, reported signs and symptoms were those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, and EPS. In one case, hyponatremia, hypokalemia, prolonged QT, and widened QRS were observed after a patient took an estimated 240 mg of oral risperidone. In another case, a patient had a seizure after taking an estimated 36 mg of oral risperidone.

Postmarketing experience with oral risperidone included reports of acute overdose with estimated doses up to 360 mg. In general, the most frequently reported signs and symptoms were those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness, sedation, tachycardia, hypotension, and EPS. Other postmarketing adverse reactions related to oral risperidone overdose included prolonged QT interval and convulsions. Torsade de pointes was reported in association with combined overdose of oral risperidone and paroxetine.

Management of Overdosage

In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. Cardiovascular monitoring should commence immediately and include continuous electrocardiographic monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of QT prolonging effects that might be additive to those of risperidone. Similarly, it is reasonable to expect that the alpha-blocking properties of bretylium might be additive to those of risperidone, resulting in problematic hypotension.

There is no specific antidote to risperidone. Therefore, appropriate supportive measures should be implemented. The possibility of multiple drug involvement should be considered. Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of risperidone-induced alpha blockade). In cases of severe EPS, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

Consider contacting the Poison Help line (1-800-222-1222) or medical toxicologist for additional overdosage management recommendations.
Patients who are diagnosed with a high grade glioma that is progressive and therapy resistance. Patients will have a KPS of 60 or less.
The evolution of sophisticated technology has brought about the rise of endoscopic strategies for managing iatrogenic esophageal perforation. This approach is reserved for stable patients with limited contamination. The most commonly performed procedures are reviewed, focusing on procedural steps and outcomes. Esophageal stenting remains the most widely implemented strategy with promising success rates. Clipping, endoluminal vacuum therapy, and suturing are also viable options. Patient selection and further study are paramount to establishing this less invasive strategy as a more standard approach.
The present invention includes a first coating section, a second coating section and a device for transferring products from the first to the second sections. The first section includes a feeding and loading station for depositing products onto product holders retained in product carrier plates. The products are advanced to a first dipping station in the first section to coat a first portion of the product. The plates are then advanced to a first rotating station in the first station and rotated at least one revolution for spreading the coating over that first portion. The plates are then advanced to a dryer that extends over the first section of the coating apparatus and the coating is dried. The transfer device transfers the products to the second section of the coating apparatus in such a manner to expose the uncoated portion of the products. The plates are then advanced to identical dipping and rotating stations and dryer as in the first section. The plates are then advanced to an unloading and discharge apparatus for emptying the product from the product holders. The empty plates are then advanced to the transfer device where they are recycled for future use.
PURPOSE: A donepezil resin complex containing donepezil and cation exchange resin is provided to shield unpleasant taste of the donepezil and to easily control drug release. CONSTITUTION: A donepezil resin complex comprises a donepezil or pharmaceutically acceptable salt and cation exchange resin. The cation exchange resin is metacrylic acid divinylbenzen resin. The content of the donepezil is 10-90 weight%. A formulation for oral administration contains the donepezil resin complex. The formulation additionally contains pharmaceutically acceptable carrier or additive.
A woman's experience with childbirth care is an important factor in her future decisions about whether to receive health care through a health care facility. Women's negative encounters with health workers long-term injury and emotional trauma can result during childbirth. Every woman has several rights. They include the following rights: 1- Freedom from harm and abuse, 2- Information, informed consent and refusal, and respect for women's choices and preferences, including companion during childbirth, 3- Privacy and confidentiality 4) Respectful and dignified treatment 5 - Equality, non-discrimination and appropriate care 6- Healthcare and attainable high standards of health and 7- Freedom, autonomy, self-determination and non-coercion. Reported forms of disrespect and abuse fell into seven categories: physical abuse, non-consensual care, non-confidential care, indecent care, discrimination based on patient characteristics, abandonment of care, and incarceration in institutions.. RMC focuses on eliminating unhealthy and abusive behaviors by healthcare providers and associated personnel, and providing a sensitive and encouraging work environment to help women feel satisfied during childbirth.To measure women's experience of respectful maternity care, vedam et la developed Mothers on Respect Index (MORi) assesses the nature of patient-provider interactions and their impact on human feelings of respect during obstetric care .The mistreatment index (MIST index), which is an indicator of abuse consistent with the seven dimensions ( physical abuse, sexual abuse, verbal abuse, stigma and discrimination. Failure to meet professional standards of care, poor rapport during interactions with Providors, and the poor state and limitations of the healthcare system )
PROBLEM TO BE SOLVED: To obtain an arterial sclerosis-suppressing agent having excellent activity and safety, containing an oligogalacturonic acid and/or its salt. SOLUTION: This arterial sclerosis-suppressing agent contains an oligogalacturonic acid of the formula and/or its salt ((n) is 0-20). Otherwise, usual components are suitably mixed and the resultant mixture can be made to a formulation such as a tablet, powder, granules, a capsule agent, a suppository, an injection and a liquid formulation by a normal method. An administrating amount of the agent is 1-2,000mg/kg, preferably 3-100mg/kg for an adult per 1 day, in dividing to 1-several times. A composition such as a food or a medicine containing the arterial sclerosis-suppressing agent has an excellent action of preventing, improving and curing an arterial sclerosis because the agent has an action excellent in reducing cholesterol in blood and suppressing arterial sclerosis.  The compound of the formula is obtained by affecting a hydrolase such as pectinase to an oligosaccharide such as pectin.
Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as hyperproduction of an inflammatory mediator caused by them, a pharmacologically acceptable salt thereof, a method for producing the same, and a pharmaceutical containing the cycloalkene derivative as an active ingredient, which is excellent in prevention and/or treatment of a disease such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure or the like). General formula (I): {In the formula, X and Y represent a group which forms the ring A with the carbon atom of the ring B to which X and Y are bound or the like. l and m independently represent an integer of 0 to 3 and l+m is 1 to 3. R1 represents an aliphatic hydrocarbon group which may be substituted or the like. n represents an integer of 0 to 3. R2 represents a hydrogen atom, an alkyl group which may be substituted or the like, R3 represents a phenyl group which may be substituted or the like, and R5 represents a hydrogen atom, an alkyl group which may be substituted or the like.}
BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
The invention discloses a gynecological rehabilitation nursing belt for postpartum rehabilitation. The gynecological rehabilitation nursing belt comprises a uterus warming belt and a plurality of cloth bags. A plurality of the cloth bags are attached to one side of the uterus warming belt close to the human body by Velcro. An electric heating blanket is arranged in the uterus warming belt. An agent for treating uterus diseases and a plurality of porous small ball carriers are arranged in each one of the cloth bags. A plurality of the porous small ball carriers are averagely placed in the cloth bags. The agent comprises, by weight, 2 to 9 portions of garden balsam stem, 4 to 15 portions of rheum officinale, 2 to 15 portions of red peony root, 2 to 15 portions of root bark of the peony tree, 1 to 4 portions of leech powder, 5 to 15 portions of poria cocos and 3 to 9 portions of peach kernels. The invention also discloses a preparation method of the gynecological rehabilitation nursing belt for postpartum rehabilitation. The electric heating blanket can preserve human body heat. The agent has effects of nourishing, treating and protecting uterus, treating dysmenorrhea and making the puerpera recover.
Obesity is one of the major risk factors for diabetes. Excessive accumulation of fat leads to inflammation of adipose tissue, which can increase the risk of developing diabetes. Obesity-related chronic inflammation can result in anomalies in glucose-lipid metabolism and insulin resistance, and it is a major cause of β-cell dysfunction in diabetes mellitus. Thus, a long-term tissue inflammatory response is crucial for metabolic diseases, particularly type 2 diabetes. Chronic inflammation associated with obesity increases oxidative stress, secretes inflammatory factors, modifies endocrine variables, and interferes with insulin signalling pathways, all of which contribute to insulin resistance and glucose tolerance. Insulin resistance and diabetes are ultimately caused by chronic inflammation in the stomach, pancreas, liver, muscle, and fat tissues. In this article, we systematically summarize the latest research progress on the mechanisms of adipose tissue inflammation and insulin resistance, as well as the mechanisms of cross-talk between adipose tissue inflammation and insulin resistance, with a view to providing some meaningful therapeutic strategies for the treatment of insulin resistance by controlling adipose tissue inflammation.
Normothermic ex vivo lung perfusion (EVLP) can resuscitate marginal lung allografts to increase organs available for transplantation. During normothermic perfusion, cellular metabolism is more active compared with subnormothermic perfusion, creating a need for an oxygen (O 2 ) carrier in the perfusate. As an O 2 carrier, red blood cells (RBCs) are a scarce resource and are susceptible to hemolysis in perfusion circuits, thus releasing cell-free hemoglobin (Hb), which can extravasate into the tissue space, thus promoting scavenging of nitric oxide (NO) and oxidative tissue damage. Fortunately, polymerized human Hb (PolyhHb) represents a synthetic O 2 carrier with a larger molecular diameter compared with Hb, preventing extravasation, and limiting adverse reactions. In this study, a next-generation PolyhHb-based perfusate was compared to both RBC and asanguinous perfusates in a rat EVLP model. During EVLP, the pulmonary arterial pressure and pulmonary vascular resistance were both significantly higher in lungs perfused with RBCs, which is consistent with RBC hemolysis. Lungs perfused with PolyhHb demonstrated greater oxygenation than those perfused with RBCs. Post-EVLP analysis revealed that the PolyhHb perfusate elicited less cellular damage, extravasation, iron tissue deposition, and edema than either RBCs or colloid control. These results show promise for a next-generation PolyhHb to maintain lung function throughout EVLP.
The present invention describes methods for treating heart diseases by pharmacological manipulation of intrinsic cardiac adrenergic cells. The activation or inhibition of δ-opioid receptors or selective β2-adrenergic receptor agonist in these cells can help regulate catecholamine synthesis and release in these cells. Thus drugs directed towards these receptors can be used in the treatment of heart diseases including acute and chronic congestive heart failure, as well as acute and chronic coronary artery disease. The present invention also describes a method of treating acute decompensated congestive heart failure using δ-opioid receptor agonists or selective β2-adrenergic receptor agonists to stimulate endogenous production of brain natriuretic peptide. This invention also provides a novel strategy for protection against myocardial ischemia through the specific activation of δ-opioid receptors or selective β2-adrenergic receptor agonists exclusively expressed by intrinsic cardiac adrenergic cells in human heart. The activation of intrinsic cardiac adrenergic cells by δ-opioid receptor stimulation enhances endogenous catecholamine release, which subsequently stimulates myocardial alpha 1-adrenoreceptors achieving myocardial protection in patients suffering from myocardial ischemia due to coronary artery disease.
In accordance with the objects outlined above, the present invention provides MRI agent compositions comprising a chelator, comprising a paramagnetic metal ion and an amyloid binding moiety (ABM). The chelator may be directly attached to the ABM or indirectly attached via a linker. The linker may be attached to either an internal or terminal position of the ABM. In an additional aspect, the invention provides ABMs that are selected from the group consisting of congo red, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy))-styrylbenzene (BSB), and chyrsamine G. These ABMs can be conjugated to chelators such as DOTA, DTPA and DOTEP comprising Gd(III). In an additional aspect, the invention provides MRI agents comprising chelators linked together using ABMs or polymers. In a further aspect, the provided pharmaceutical composition comprises an MRI agent of the invention and a pharmaceutically acceptable carrier. In an additional aspect, the present invention provides methods of magnetic resonance imaging of a cell, tissue or patient comprising administering an MRI agent of the invention to a cell, tissue or patient and rendering a magnetic resonance image of the cell, tissue or patient.
UI is a very common condition whose prevalence can be expected to increase dramatically in the coming decades. Treatment options are available to improve women's health and quality of life. However, inadequate communication between physicians and patients leads to decreased diagnosis and treatment. Past studies evaluating the use of screening by primary care providers, who act as gatekeepers in our healthcare system, clearly demonstrate that improvements must be made in the screening system. We propose a survey of local primary care providers to quantify screening rates for UI and identify barriers to successful screening. The information collected in this survey will allow us to identify methods such as targeted education opportunities and patient literature or questionnaires that will assist providers and their patients in initiating discussion and evaluation of UI.
Hypokalemia is a common laboratory finding in hospitalized patients, typically resulting from insufficient potassium intake, renal or gastrointestinal losses, or intracellular shifts. While the underlying cause is often easily identifiable, certain cases present diagnostic challenges, and if left unrecognized, the consequences can be life-threatening. We report a rare and atypical case of severe symptomatic hypokalemia as the initial presentation of newly diagnosed Graves' disease. The condition was caused by thyrotoxic periodic paralysis, a rare but serious complication of thyrotoxicosis, predominantly seen in East Asian populations. This disorder is characterized by episodes of acute, reversible muscle weakness associated with transient hypokalemia, which increases the risk of falls and traumatic injuries. The prompt identification of the etiology in such cases is critical for preventing recurrence and avoiding potentially fatal complications.
A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
The invention relates to the field of medicine preparations, in particular to Chinese herbal medicine skin quick-acting nursing liquid with the functions of tightening the skin and resisting wrinkles. The Chinese herbal medicine skin quick-acting nursing liquid with the functions of tightening the skin and resisting wrinkles is a content filled into a bottle. A formula comprises the following components: 20-30% of angelica extract, 2-3% of water soluble pearl powder, 2-3% of carrageenan, 2-3% of guajiao, 0.1-0.3% of baidusha and 70-80% of medical stone soaking liquid. Compared with the prior art, the invention utilizes various trace elements which are in medical stone and are beneficial to the skin of a human body, angelica containing various nutritional components of protein, amino acid and the like and the water soluble pearl powder with the functions of healing and promoting tissue regeneration are added as the effective components of the preparation, and plant collagen prepared by decocting the carrageenan and the guajiao which contain various nutritional components and polysaccharide is prepared into the Chinese herbal medicine skin quick-acting nursing liquid with the functions of tightening the skin and removing wrinkles according to a technological process. By nutrition osmosis, healing and tissue regeneration promotion, the effects of tightening the skin and removing wrinkles are achieved. The invention has convenient and proper operation and is suitable for the department of dermatology in hospitals, specialized beauty parlors and families.
Participants in this arm will not receive probiotic supplementation. They will be followed in a similar way as the participants in the probiotic eK12 group.
Previous researchers have attempted to establish a "target dose" for antipsychotic medications (such as risperidone, quetiapine, or olanzapine) in treating symptoms of agitation in dementia. They have tried to identify the dose with the best risk-benefit ratio for patients considering the significant side effects the medications can cause. Patients taking the doses identified respond only partially and continue to experience some symptoms of agitation, however. One study showed that in patients whose agitation symptoms were not adequately controlled by the target dose of an antipsychotic medication alone, the addition of divalproex further improved behavior in 72% of patients.

The goal of this study is to compare two standard therapies for the management of agitation symptoms in dementia patients. Subjects in this study will include patients who are admitted to the Wesley Woods Inpatient service for the treatment for dementia complicated by behavioral symptoms. After a patient reaches the target dose of risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day) and agitation symptoms are still not adequately managed, he or she will be randomized to one of two groups. Group 1 participants will continue to receive increasing doses of antipsychotic medication until symptoms are controlled or he or she is unable to tolerate the dose. Group 2 participants will continue to receive the target dose of antipsychotic medication and also receive increasing doses of divalproex until symptoms are controlled or he or she is unable to tolerate the dose. Patients will be evaluated at 4 time points during hospitalization. Patients will be evaluated using scales that measure changes in cognition, function, and behavior. Laboratory and ECG results, and scales testing for movement disorders will be done to monitor safety. The family will then be contacted about 3 months the patient's hospitalization to assess current treatment status, residential status, and health status.
Statin therapy, especially at intensive doses, is beneficial in atherosclerotic coronary disease. Detecting subtle plaque regression after statin therapy is difficult by coronary angiogram; intravascular ultrasound (IVUS) is a far better method. Volumetric IVUS has been used in statin trials to evaluate plaque regression. Intensive statin therapy in the REVERSAL Trial and ASTEROID Trial appeared to achieve better regression outcomes. Stable fibrous plaque is likely to be responsible for stable ischemia, while unstable plaque (large lipid core, calcified nodule and necrotic core), thin-cap fibroatheroma, plaque erosion and plaque rupture may be responsible for acute coronary syndrome (ACS). In vivo tissue characterization of plaque composition is therefore important, yet in this regard grayscale IVUS is insufficient. The development of Virtual Histology (VH) utilizing IVUS generated radiofrequency backscattering signals to virtually separate plaque composition into 4 components corresponding to histopathology has made possible in vivo assessment of plaque composition and stability. We believed plaque regression and VH-IVUS plaque modification with statin therapy could be statin dose dependent, and may affect clinical outcomes. This study was designed to prove our hypothesis, utilizing VH-IVUS.

This study is the first prospective, randomised, double-blinded pilot study designed to investigate the varying statin dose effects on plaque regression and VH composition modulation. For ethical reasons, a placebo arm was not designed. Based on available data, clinically realistic doses of atorvastatin 10mg (low dose) and 40mg (moderate dose) were chosen. Only statin-naïve patients without previous history of myocardial infarction (MI) would be selected, aiming to show the "pure" effects of varying doses of statin and to better reveal the subtle differences in the changes.